← All indications
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Subtype terms (9)
More specific conditions that are subtypes of Anemia in the MeSH hierarchy.
- Anemia, Aplastic
105 drugs (64 approved, 41 experimental)
- Anemia, Hemolytic
20 drugs (18 approved, 2 experimental)
- Anemia, Hypochromic
2 drugs (1 approved, 1 experimental)
- Anemia, Macrocytic
1 drug experimental
- Anemia, Myelophthisic
- Anemia, Neonatal
5 drugs (1 approved, 4 experimental)
- Anemia, Refractory
62 drugs (36 approved, 26 experimental)
- Anemia, Sideroblastic
- Red-Cell Aplasia, Pure
18 drugs (15 approved, 3 experimental)
Drugs by status
Approved for this indication (63)
- sodium citrate
- ferric derisomaltose
- cladribine
- decitabine
- azacitidine
- iron
- methylprednisolone
- calcium carbonate
- darbepoetin alfa
- epoetin
- lenalidomide
- methoxy polyethylene glycol-epoetin beta
- daprodustat
- prednisone
- stanolone
- betamethasone
- docusate
- erythropoetin beta
- felbamate
- ferrous fumarate
- ferric carboxymaltose
- ferric citrate
- folic acid
- cyanocobalamin
- Imetelstat
- potassium iodide
- iron dextran
- iron hydroxide adipate
- iron sucrose
- liposomal iron
- +33 more
Phase 4 trials (57)
- vitamin d3
- albendazole
- cinacalcet
- oxytocin
- acetylcysteine
- carbetocin
- deferoxamine
- deferasirox
- ferric sulfate
- fumaric acid esters
- cobalamin
- artesunate
- deferiprone
- enarodustat
- levocarnitine
- praziquantel
- red blood cells
- allogeneic hematopoietic stem cells
- ribavirin
- roxadustat
- romiplostim
- cyclosporine
- cyclophosphamide
- sucrosomial iron
- sulfamethoxazole
- Anti-thymocyte Globulin (Rabbit)
- calcitriol
- cellulose
- paricalcitol
- betahistine mesilate
- +27 more
Phase 3 trials (34)
- diclofenac
- corticotropin
- urea
- ferric maltol
- iron glycinate
- paclitaxel
- goserelin
- heme iron polypeptide
- mebendazole
- molidustat
- octreotide
- pazopanib
- ibrutinib
- carboplatin
- sotatercept
- progenta
- estradiol
- whole blood
- s303 red blood cells
- fludarabine
- allogeneic blood cells
- azithromycin
- amino acids
- rituximab
- misoprostol
- multivitamins
- ferroglycine sulfate
- tinzaparin
- choline
- desidustat
- +4 more
Phase 2 trials (65)
- lutetium (177Lu) vipivotide tetraxetan
- thalidomide
- vitamin e
- amg 114
- amifostine
- oxandrolone
- autologous t cells
- bendamustine
- busulfan
- canakinumab
- danazol
- eltrombopag
- entospletinib
- ferric saccharose
- fmx-8
- obinutuzumab
- tacrolimus
- naltrexone
- hetrombopag olamine
- hydroxyurea
- xenon-129
- Filgrastim
- acetylcholine chloride
- jobelyn
- leridistim
- levamisole
- lexaptepid pegol
- nitric oxide
- nitroprusside
- pegol-sihematide
- +35 more
Phase 1 trials (56)
- afatinib
- ag-519
- olaparib
- sorafenib
- venetoclax
- ds-1093
- enzalutamide
- gemfibrozil
- fluorouracil
- imatinib
- trametinib
- hemopoietic stem cell
- rosuvastatin
- idelalisib
- nivolumab
- pembrolizumab
- lenvatinib
- leucovorin
- pegylated carboxyhemoglobin
- palbociclib
- panobinostat
- ponatinib
- caffeine
- ipilimumab
- sunitinib
- lactoferrin
- pertuzumab
- vemurafenib
- sitagliptin
- celecoxib
- +26 more
Other trials (51)
- autologous blood
- beta erythropoietin
- iron acetyl-transferase
- bone autograft
- carfilzomib
- ketamine
- iron hydroxide dextran
- ferrous glycine sulphate complex
- ferrous ascorbate
- iron succinate
- hemoglobin glutamer 250
- ritonavir
- icosapent ethyl
- etomidate
- ferroven
- natureheme
- nitazoxanide
- acetylsalicylic acid
- dapsone
- endotoxin
- wild-type reovirus
- furosemide
- autologous cd34+ cells
- moringa oleifera
- chlorproguanil
- angelica
- iron colloid
- ferritin
- transferrin
- ferric hydroxide-polymaltose
- +21 more
Organizations
Organization Involved with Phase 4 Indications (163)
- Keryx
- IHS Dialysis Centre, Sf Ioan Nou Clinical Hospital
- Allama Iqbal Medical College
- Harbin Medical University
- Jiao Tong University
- Jiangxi Provincial People's Hospital
- Shire
- The Japan Kidney Foundation
- Eastern Health, Canada
- Parexel
- University of Split
- Martin Luther University
- Pediatric Specialists of Virginia
- Jordi Gol i Gurina Foundation
- Tai'an Central Hospital
- Vifor Inc.
- University of London
- Aarhus University
- University of Athens
- University of Kinshasa
- Akebono clinic
- Guangzhou Medical University
- Pharmacosmos
- University of Granada
- National Health and Medical Research Council, Australia
- Qingdao Center Medical Group
- Federal University of Juiz de Fora
- National Cancer Institute (NCI)
- Capital Medical University
- Schering-Plough
- +133 more
Organization Involved with Phase 3 Indications (181)
- Mitsubishi Tanabe
- Emmaus Medical
- University of Melbourne
- Taipei Veteran General hospital
- UBI Pharma Inc.
- BioStata
- Government of Malaysia
- International Center for Diarrheal Disease Research
- Norwegian University of Science and Technology
- University of Liverpool
- INC Research
- Gazi University
- University of Minnesota
- Tropical Medicine Research Institute
- Government of Malawi
- Gelre Hospitals
- Barts & The London NHS Trust
- Department of Veteran Affairs
- Radboud University
- Free University of Amsterdam
- University of Western Australia
- University of Ljubljana
- Clinical Trials and Surveys Corp
- Celgene
- Reinier de Graaf Groep
- ClinStar, LLC
- Columbia University
- Cadila Healthcare
- Takeda
- Baylor University
- +151 more
Organization Involved with Phase 2 Indications (131)
- Foresee Pharmaceuticals Co., Ltd.
- Good Samaritan Hospital, Cincinnati
- The Korean Society of Pediatric Hematology Oncology
- Blood and Marrow Transplant Clinical Trials Network
- Annexon
- University of Seville
- Mercy Hospital and Medical Center, Illinois
- Red de Terapia Celular
- University of Bordeaux
- Shantou University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Limoges
- Norton Healthcare
- The Second People's Hospital of GuangDong Province
- Yeshiva University
- Boston University
- Government of Sudan
- European Organisation for Research and Treatment of Cancer
- University of North Carolina at Chapel Hill
- National Center for Research Resources (NCRR)
- Fresenius
- Merck
- Hebrew University
- Centocor
- Noxxon AG
- North Central Cancer Treatment Group
- EuroFancolen
- Leiden University
- Feinstein Institute for Medical Research
- Spanish National Health System
- +101 more
Organization Involved with Phase 1 Indications (21)
- Duzce University
- China Spinal Cord Injury Network
- Chinese University of Hong Kong
- Hillhurst Biopharmaceuticals, Inc.
- Prolong Pharmaceuticals
- University of South Florida
- Octagon Research Solutions, Incoporated
- Cyprus University of Technology
- Syntimmune, Inc.
- University of Alabama
- Mononuclear Therapeutics Ltd.
- University of Kansas
- Hebei University
- Eleos, Inc.
- Mallinckrodt
- Virginia Commonwealth University
- Children's Hospital Los Angeles
- BioChemAnalysis Corp.
- Pierre Fabre
- Damon Runyon Cancer Research Foundation
- University of Guelph
Organization Involved with Other Experimental Indications (75)
- Dow University of Health Sciences
- Government of Scotland
- University of Edinburgh
- European Hospital
- University of Colorado
- Icahn School of Medicine at Mount Sinai
- King Hussein Cancer Center
- Procter and Gamble
- Government of France
- Centers for Disease Control and Prevention (CDC)
- Dartmouth University
- Calidad Pascual
- Institut National d'Etude et d'Action pour le Developpement de l'Education, Senegal
- Government of Brazil
- Joint Clinical Research Centre, Kampala, Uganda
- Arogyavaram Medical Centre
- Federal University of Goias
- National Center for Complementary and Integrative Health (NCCIH)
- Hikma
- University of Ferrara
- Ruhr University Bochum
- University of Missouri
- Sao Jose do Rio Preto University
- Government of Hong Kong
- Englewood Hospital and Medical Center
- Hospital Infantil Dr. Robert Reid Cabral
- Five Rivers Health Centers
- University of Tuebingen
- University of Brasilia
- Tanta University
- +45 more